# CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer

> **NCT05251714** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Treadwell Therapeutics, Inc** · enrollment: 44 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Breast Cancer

## Interventions

- **DRUG:** CFI-402257
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT05251714
- **Lead sponsor:** Treadwell Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-05-27
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2025-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05251714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05251714, "CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05251714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*